Keeping Track: J&J Submits Ponesimod NDA For MS; US FDA Clears Epclusa For Pediatric HCV

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

Keeping Track Feature image

New drug applications continue to arrive at the US Food and Drug Administration during the coronavirus crisis, as demonstrated by submissions from Janssen Pharmaceutical Cos., Mallinckrodt PLC, and Aurinia Pharmaceuticals Inc..

Janssen is seeking an indication in relapsing multiple sclerosis for ponesimod, the Johnson & Johnson company announced 18 March...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA Performance Tracker

More from Regulatory Trackers